- IV infusionPertuzumabInhibits ligand-dependent HER2 dimerisation and signalling
- Mechanism of Action
- A monoclonal antibody directed against the HER2 receptor, which is involved in cell signalling and is overexpressed in certain cancers. Inhibition of HER2 signalling pathways results in cell cycle arrest; the monoclonal antibody also mediates antibody-dependent cell-mediated cytotoxicity.
- HER2 positive breast cancer
- Adverse Effects